Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).
cgi pharmaceuticals
Fall Allergy Season Is Upon Us
Ragweed season is under way, bringing with it sneezes, sniffles, and itchy eyes for 36 million Americans.